Compare Aurobindo Pharma with Natco Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AUROBINDO PHARMA vs NATCO PHARMA - Comparison Results

AUROBINDO PHARMA     Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AUROBINDO PHARMA NATCO PHARMA AUROBINDO PHARMA/
NATCO PHARMA
 
P/E (TTM) x 10.5 20.0 52.5% View Chart
P/BV x 1.9 3.2 61.4% View Chart
Dividend Yield % 0.5 1.1 50.8%  

Financials

 AUROBINDO PHARMA   NATCO PHARMA
EQUITY SHARE DATA
    AUROBINDO PHARMA
Mar-19
NATCO PHARMA
Mar-19
AUROBINDO PHARMA/
NATCO PHARMA
5-Yr Chart
Click to enlarge
High Rs830849 97.8%   
Low Rs527557 94.6%   
Sales per share (Unadj.) Rs333.9573.8 58.2%  
Earnings per share (Unadj.) Rs40.4176.0 22.9%  
Cash flow per share (Unadj.) Rs51.8198.2 26.1%  
Dividends per share (Unadj.) Rs2.506.25 40.0%  
Dividend yield (eoy) %0.40.9 41.4%  
Book value per share (Unadj.) Rs237.1842.7 28.1%  
Shares outstanding (eoy) m585.9136.50 1,605.2%   
Bonus/Rights/Conversions ESOPBB-  
Price / Sales ratio x2.01.2 165.9%   
Avg P/E ratio x16.84.0 421.0%  
P/CF ratio (eoy) x13.13.5 369.6%  
Price / Book Value ratio x2.90.8 343.1%  
Dividend payout %6.23.6 174.4%   
Avg Mkt Cap Rs m397,56925,660 1,549.4%   
No. of employees `00017.95.0 360.2%   
Total wages/salary Rs m25,8493,559 726.3%   
Avg. sales/employee Rs Th10,956.94,225.3 259.3%   
Avg. wages/employee Rs Th1,447.7718.0 201.6%   
Avg. net profit/employee Rs Th1,324.31,295.9 102.2%   
INCOME DATA
Net Sales Rs m195,63620,945 934.0%  
Other income Rs m1,5531,302 119.3%   
Total revenues Rs m197,18922,247 886.4%   
Gross profit Rs m39,5197,948 497.2%  
Depreciation Rs m6,680810 824.6%   
Interest Rs m2,626193 1,360.6%   
Profit before tax Rs m31,7678,247 385.2%   
Minority Interest Rs m270-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-8810-   
Tax Rs m7,2691,823 398.7%   
Profit after tax Rs m23,6456,424 368.1%  
Gross profit margin %20.237.9 53.2%  
Effective tax rate %22.922.1 103.5%   
Net profit margin %12.130.7 39.4%  
BALANCE SHEET DATA
Current assets Rs m153,64523,472 654.6%   
Current liabilities Rs m120,4297,287 1,652.7%   
Net working cap to sales %17.077.3 22.0%  
Current ratio x1.33.2 39.6%  
Inventory Days Days13592 146.6%  
Debtors Days Days6488 72.2%  
Net fixed assets Rs m103,90918,648 557.2%   
Share capital Rs m586365 160.5%   
"Free" reserves Rs m138,32234,525 400.6%   
Net worth Rs m138,90830,760 451.6%   
Long term debt Rs m1,8000-   
Total assets Rs m264,54443,031 614.8%  
Interest coverage x13.143.7 29.9%   
Debt to equity ratio x00-  
Sales to assets ratio x0.70.5 151.9%   
Return on assets %9.915.4 64.6%  
Return on equity %17.020.9 81.5%  
Return on capital %23.827.4 86.9%  
Exports to sales %49.60-   
Imports to sales %18.80-   
Exports (fob) Rs m97,091NA-   
Imports (cif) Rs m36,741NA-   
Fx inflow Rs m97,31611,536 843.6%   
Fx outflow Rs m40,5892,939 1,381.1%   
Net fx Rs m56,7278,597 659.8%   
CASH FLOW
From Operations Rs m16,2206,688 242.5%  
From Investments Rs m-28,768-6,122 469.9%  
From Financial Activity Rs m19,191-509 -3,770.3%  
Net Cashflow Rs m6,65666 10,085.5%  

Share Holding

Indian Promoters % 54.1 52.0 104.0%  
Foreign collaborators % 0.0 1.5 -  
Indian inst/Mut Fund % 8.0 7.8 101.4%  
FIIs % 27.7 16.6 166.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.2 26.0 39.2%  
Shareholders   69,601 25,395 274.1%  
Pledged promoter(s) holding % 8.6 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AUROBINDO PHARMA With:   ASTRAZENECA PHARMA  DR. DATSONS LABS  CADILA HEALTHCARE  NOVARTIS  PANACEA BIOTECH  

Compare AUROBINDO PHARMA With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Surges 1,266 Points; Nifty Ends Above 9,100 Mark(Closing)

Indian share markets witnessed buying interest throughout the day and ended on a strong note.

Related Views on News

NILKAMAL Surges by 13%; BSE 500 Index Up 2.2% (Market Updates)

Apr 9, 2020 | Updated on Apr 9, 2020

NILKAMAL share price has surged by 13% and its current market price is Rs 1,160. The BSE 500 is up by 2.2%. The top gainers in the BSE 500 Index are NILKAMAL (up 13.0%) and NATCO PHARMA (up 10.3%). The top losers are GODFREY PHILLIPS and NARAYANA HRUDAYALAYA LTD (down 0.1%).

NATCO PHARMA Surges by 10%; BSE HEALTHCARE Index Up 3.5% (Market Updates)

Apr 9, 2020 | Updated on Apr 9, 2020

NATCO PHARMA share price has surged by 10% and its current market price is Rs 635. The BSE HEALTHCARE is up by 3.5%. The top gainers in the BSE HEALTHCARE Index is NATCO PHARMA (up 10.3%). The top losers are NARAYANA HRUDAYALAYA LTD (down 0.1%) and LAURUS LABS LTD (down 0.6%).

NATCO PHARMA Announces Quarterly Results (3QFY20); Net Profit Down 34.5% (Quarterly Result Update)

Feb 17, 2020 | Updated on Feb 17, 2020

For the quarter ended December 2019, NATCO PHARMA has posted a net profit of Rs 1 bn (down 34.5% YoY). Sales on the other hand came in at Rs 5 bn (down 13.4% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (3QFY20); Net Profit Down 0.5% (Quarterly Result Update)

Feb 7, 2020 | Updated on Feb 7, 2020

For the quarter ended December 2019, AUROBINDO PHARMA has posted a net profit of Rs 7 bn (down 0.5% YoY). Sales on the other hand came in at Rs 58 bn (up 10.1% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (2QFY20); Net Profit Up 4.6% (Quarterly Result Update)

Nov 15, 2019 | Updated on Nov 15, 2019

For the quarter ended September 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 4.6% YoY). Sales on the other hand came in at Rs 56 bn (up 17.9% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

More Views on News

Most Popular

Sorry Warren Buffett, I'm Following This Man Instead of You in 2020(The 5 Minute Wrapup)

Mar 30, 2020

This man warned of an impending market correction while everyone else was celebrating the renewed optimism in early 2020...

One Stock that is All Charged Up for the Post Coronavirus Rebound(The 5 Minute Wrapup)

Apr 1, 2020

A stock with strong moat is currently trading near 5-year lows.

A Safe Stock to Lockdown Now(The 5 Minute Wrapup)

Apr 2, 2020

The market crashc has made strong, established brands attractive. Here's a stock to make the most of this opportunity...

The Insiders See a Buying Opportunity in These Smallcaps Amid Coronavirus Outbreak(Profit Hunter)

Mar 31, 2020

The promoters are buying these smallcaps amid the coronavirus outbreak.

How to Identify a Market Rebound(Fast Profits Daily)

Mar 27, 2020

This very useful indicator can spot a market bottom.

More

How to Trade the
Coronavirus Crash

Coronavirus Crash
Get this special report, authored by Equitymaster's top analysts, now.
We will never sell or rent your email id.
Please read our Terms

AUROBINDO PHARMA SHARE PRICE


Apr 9, 2020 (Close)

TRACK AUROBINDO PHARMA

  • Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AUROBINDO PHARMA

AUROBINDO PHARMA 8-QTR ANALYSIS

COMPARE AUROBINDO PHARMA WITH

MARKET STATS